Slide 1: Investor resource book Fourth quarter 2022
Making improvements in life possible Investor resource book Fourth quarter 2022 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: Table of Contents
Table of Contents About QIAGEN 4 QIAGEN at a glance 6 Global presence 12 Strategy 13 Debt information 19 Capital allocation 20 Why invest 21 Business areas 22 Product portfolios 25 Sample technologies 27 Diagnostic solutions 32 PCR / Nucleic acid amplification 47 Genomics / NGS 55 Sustainability 63
Slide 4: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Q4 2022 Investor Resource Book 4
Slide 5: QIAGEN provides solutions to uncover molecular insights from Sample to Insight
QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight Biological Sample to Valuable sample Insight solutions molecular insights • Sample Technologies • Advancing knowledge about the building • Assay Technologies blocks of life – DNA, R
Slide 6: QIAGEN at a glance
QIAGEN at a glance Our products support scientists and clinicians to advance scientific discovery and improve patient outcomes A global company with scale Balanced customer markets $2.2 bn ~50% ~50% >500,000 (2021 sales) Molecular customers Life Diagnostics Sciences worldwide Diverse global presence
Slide 7: Unprecedented need for molecular research and testing
There is an unprecedented need for molecular research and testing to tackle the health challenges of our time Our knowledge about Tuberculosis is still Cancer remains a Infectious diseases the building blocks of one of the world’s leading cause of have been – and life – DNA, RNA and most significant
Slide 8: Our products are found in laboratories worldwide
Our products are found in laboratories worldwide - from young scientists to Nobel laureates Q4 2022 Investor Resource Book 8
Slide 9: We help over 500,000 customers unlock molecular insights
We help over 500,000 customers unlock molecular insights that address healthcare challenges. That’s how we help make improvements in life possible. Q4 2022 Investor Resource Book 9
Slide 10: We are COVID relevant – but not COVID dependent
We are COVID relevant – but not COVID dependent >750 million COVID-19 tests in 2021 relied on QIAGEN products Testing Surveillance • RNA sample preparation • Immune level testing • PCR testing solutions • NGS variant monitoring • OEM components • Wastewater testing for other suppliers Q4 2022 Invest
Slide 11: Ready to serve public health needs across the globe
And we are ready to serve public health needs across the globe Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships TB testing for low-resource Testing for high-risk human Sample technologies high-burden regions with papillomavirus (HPV) using supporti
Slide 12: Global presence with focus on attractive markets
Global presence with a focus on the most attractive developed and emerging markets Our global and regional headquarters Venlo Netherlands 35 subsidiaries Global HQ Germantown Maryland Americas HQ Distribution Hilden partners in over 25 Germany in over 60 EMEA HQ Shanghai China Asia-Pacific HQ countr
Slide 13: Our Strategy: Focus on areas to build leading positions
Our Strategy: Focus on areas to build and maintain leading positions Expanding on solid leadership Early commercialization phases with strong growth potential Nr. 1 in QuantiFERON for QIAstat-Dx for NeuMoDx for Leading the way Sample technologies immune response near-patient syndromic mid- to high-t
Slide 14: Five pillars of growth: Advancing key drivers
Five pillars of growth: Advancing key drivers to capture large opportunities Targeting >$6 billion of our >$11 billion total addressable market Sample technologies QuantiFERON QIAstat-Dx NeuMoDx QIAcuity • Leading reputation, • Fully automated • Sample prep in <1 • Faster time to result • Rapid time
Slide 15: Five pillars of growth: Expected trends in 2022 and beyond
Five pillars of growth: Expected trends in 2022 and beyond Cumulative 2022 placements sales goals Post-COVID dynamics (As of Jan 2022) (CER) QIAsymphony >3,000 Sustainable low- to mid- Sample technologies >$750 m QIAcube >13,000 single-digit CER growth EZ1 and EZ2 >4,800 Sustainable low-double-digit
Slide 16: FY 2021: Solid growth trends beyond COVID
FY 2021: Solid growth trends beyond COVID in all product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) +19% CER +19% CER $2,252 $2,252 $1,870 $1,870 851 Sample technologies +4% CER 1,547 Non-COVID 804 product groups 1,252 Diagnostic +
Slide 17: FY 2021: Investing in the business while building value
FY 2021: Investing in the business while building value Adj. operating income Adjusted EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers $639 ~65% of R&D spending focused on five pillars of growth 190 $458 $755 $2.65 Disciplined operating
Slide 18: Outlook: Q4 and FY 2022
Outlook: Q4 and FY 2022 Q4 2022 outlook Updated FY 2022 outlook ~ $2.25 billion CER Net sales > $520 million CER Adverse FX impact of ~ -6 p.p. Anticipated currency impact Adverse FX impact of ~ -7 p.p (Previously: ≥ $2.2 bn CER) Non-COVID product groups Double-digit CER growth Double-digit CER grow
Slide 19: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2021 Maturities of debt instruments $2.02 billion $1.06 billion (In $ millions) Cash and short-term U.S. Private Placement Schuldschein Convertible Bonds Convertible investments Bonds 117 2023 2024 635 2027 $957
Slide 20: Supporting growth while increasing returns to shareholders
Supporting growth while increasing returns to shareholders Healthy cash flow trends Invest in the business 500 1.8 1.5x Fuel sustainable and profitable 1.6x 0.9x 1.5x 1.6 growth, especially in the five pillars 1.4x 400 1.4 458 449 1.2 Enhance value with M&A 300 359 1.0 Ongoing disciplined approach w
Slide 21: Why invest in QIAGEN
Why invest in QIAGEN: Strong de-risked investment case with compelling differentiation Highly recurring Broad geographic Diversified customer revenues reach base Sales driven by steady customer Robust structures securing access to Well-balanced sales split between shipments of high margin consumable
Slide 22: Life Sciences: Enabling the advancement of science
Life Sciences: Enabling the advancement of science QIAGEN value ~$5 billion 2021 sales Academia addressable market of ~$1.1 billion Recognized innovator supporting breakthrough science Pharma Ability to translate ~5-6% CER innovations into market growth (excl.COVID) commercial products Applied Testi
Slide 23: Molecular Diagnostics: Improving outcomes for patients
Molecular Diagnostics: Improving outcomes for patients QIAGEN value ~$6 billion 2021 sales of ~$1.1 billion addressable market Focused on high-growth, high-demand opportunities Strong automation portfolio with multi-year assay menu ~6-7% CER expansion underway Clinical market growth (excl.COVID) hea
Slide 24: Bioinformatics: Genomic data analysis and interpretation
Bioinformatics: Offering unique genomic data analysis and interpretation capabilities QIAGEN value Clinical Healthcare ~$620 million 2021 sales: ~$89 million addressable market Academia Industry leader in commercial bioinformatics solutions Pharma Offering solutions in ~15% CER combination with the
Slide 25: QIAGEN product portfolios
QIAGEN product portfolios Sample to Insight
Slide 26: Reporting sales in product groups
Reporting sales in product groups QIAGEN Five pillars of growth product groups Sample technologies(1) QIAcuity digital PCR(3) QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control includin
Slide 27: Sample technologies
Sample technologies Customers Sample collection, stabilization Manual sample preparation and storage solutions Life Sciences Academic Pharma Applied testing Molecular Diagnostics Automated sample preparation Quality control instruments Q4 2022 Investor Resource Book 27
Slide 28: The first step in virtually any molecular biology process
The first step in virtually any Sample technologies molecular biology laboratory process QIAGEN holds leading products in the vast majority of applications mRNA microRNA Total RNA from FFPE tissue Gel extraction Post-reaction cleanup ~70-75% Total RNA from whole (i.e. PCR, enzyme of QIAGEN sample bl
Slide 29: Our Sample technologies are the foundation of QIAGEN
Our Sample technologies are the foundation of QIAGEN Sample technologies A portfolio that has grown to address the complete spectrum of processing biological samples Selected biological samples Applications Tissue Stool Input demands Processing Target analytes Cloning qPCR / dPCR Cells Saliva Low /
Slide 30: Building on Sample Technologies solid leadership
Building on Sample Technologies solid leadership Sample technologies Upgrading key automation platforms Comprehensive consumables portfolio QIAcube Connect EZ2 Connect QIAsymphony Boost Launched 2019 Launched 2021 In development Over 300 kits • Any sample format Add photo • Any analyte for QS (DNA,
Slide 31: SPOTLIGHT: QIAsymphony
SPOTLIGHT: QIAsymphony – Sample technologies Flagship platform for sample processing Off-the-shelf solutions and customizable protocols to fit wide range of laboratory needs Front-end automation solution for molecular testing Regionalization strategy • US: Focus on sample technologies • Rest-of-worl
Slide 32: Diagnostic solutions
Diagnostic solutions Customers Immune Response Infectious diseases Molecular Diagnostics Women’s Health Oncology and Precision Medicine Q4 2022 Investor Resource Book 32
Slide 33: Immune Response: Best-in-class IGRA test for latent TB
Immune Response: Best-in-class IGRA Diagnostic solutions test for latent tuburculosis What is QuantiFERON? Latent TB testing market QuantiFERON-TB Gold Plus (QFT-Plus) is a simple blood test that aids in the detection >$1 QIAGEN of Mycobacterium tuberculosis, the bacteria which causes tuberculosis (
Slide 34: Growing market demand for modern latent TB testing
A growing market demand Diagnostic solutions for modern latent TB testing What is the difference between latent TB ~70 million latent TB tests per year across the world and active TB? Latent TB infection (LTBI) can persist for weeks, months or years North before developing into active disease. Altho
Slide 35: QuantiFERON fully automated workflows
QuantiFERON offers fully automated workflows Diagnostic solutions for low and high throughput testing Enabling hands-free processing QuantiFERON differentiation of QFT-TB Gold Plus Full automation capability DiaSorin Strong best-in-class LIASON XS & XL Highly specific market No inter-reader variabil
Slide 36: QuantiFERON Lyme
QuantiFERON Lyme: Combination of Diagnostic solutions tests allowing a new level of detection CE-IVD test launched in 2021 Rising occurrence of Lyme disease 40,000 Confirmed cases Potential testing market Europe ~35,000 per year ~12-14 million tests per year U.S. ~30,000 per year ~5 million tests pe
Slide 37: Infectious diseases: New generation of PCR technology
Infectious diseases: New generation Diagnostic solutions of PCR technology for urgent needs Core / Hospital laboratories Near-patient clinical laboratories Hospital and Community hospitals and reference lab networks reference lab “outreach” centers Market opportunity Requirements: Requirements: Mark
Slide 38: QIAstat-Dx: Capturing opportunities in syndromic testing
QIAstat-Dx: Capturing Diagnostic solutions opportunities in the rapidly growing market of syndromic testing What is syndromic testing? Syndromic testing is a new approach to molecular diagnostic testing which uses a single test to look for multiple viral, bacterial or fungal infections. Sets of comm
Slide 39: QIAstat-Dx: Reliable, fast and cost-effective diagnosis
QIAstat-Dx: Reliable, fast and cost-effective Diagnostic solutions diagnosis of complex syndromes Unrivaled ease-of-use Liquid / solid sample input Dry swab sample input Self- contained cartridge Real-time PCR reaction chambers Analytical modules Operational module • Small footprint with More than a
Slide 40: QIAstat-Dx: Expanding menu in U.S. and Europe
QIAstat-Dx: Expanding menu Diagnostic solutions in U.S. and Europe Growing test menu Broadening the addressable market with QIAstat-Dx Rise CE-IVD FDA Respiratory Respiratory SARS CoV-2 Small hospitals Medium-sized hospitals National reference labs, Public health labs Regional reference labs Large I
Slide 41: QIAstat-Dx: Novel syndromic testing system
QIAstat-Dx: Diagnostic solutions Novel syndromic testing system delivering unique value QIAstat-Dx (4 scalable slots QIAstat-Dx - Rise Biofire FilmArray Biofire Torch Luminex ePlex Genmark Verigene used for (1 slot) (12 slots) (12 slots) (1 slot) comparison) Throughput (in 8 hours) 28 56 9 108 60 4
Slide 42: NeuMoDx: Simplicity of clinical chemistry to integrated PCR
NeuMoDx: Bringing simplicity of clinical Diagnostic solutions chemistry to integrated PCR testing New generation of integrated PCR NeuMoDx differentiation • Easier: Three-step workflow process Two scalable platforms: 96 and 288 • Faster: First results in ~1 hour Fully acquired in September 2020 • Mo
Slide 43: NeuMoDx: Unique integrated PCR platform in >$3 billion market
NeuMoDx: A unique integrated PCR testing Diagnostic solutions platform in >$3 billion market opportunity Roche Cobas Hologic Hologic 6800 Roche Cobas Beckman Veris NeuMoDx 288 NeuMoDx 96 Abott Alinity M Panther Panther Fusion (+ Omni LDT 8800 (Discontinued) channel) Volume in '00,000s cm3 38 16 18 2
Slide 44: Oncology and Precision Medicine: Partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice CDx and LDT Market >25 >$1.1 billion annually ~15% CAGR pharma partnerships Currently mostly LDT’s Day One Lab Readiness program Program designed to further accelerate the access of cancer patients to QIAGEN’s compan
Slide 45: Oncology and Precision Medicine: Partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice QIAGEN molecular diagnostic development 2021 sales: ~$80 million 26 IVD development programs either in pre-clinical or clinical phase • ~50% Pharma co- Offering both development revenues PCR and NGS technologies 20 C
Slide 46: Women's Health: Prenatal testing and STD detection
Women’s Health: Prenatal Diagnostic solutions testing and detection of sexually transmitted diseases Cervical cancer screening Digene – Comprehensive range of human papillomavirus DNA test Maternal / Fetal testing AmniSure – For the detection of PAMG-1 in amniotic fluid of pregnant women PartoSure –
Slide 47: PCR / Nucleic Acid amplification
PCR / Nucleic Acid amplification Customers Digital PCR - QIAcuity PCR reagents and instrumentation Life Sciences Academic Pharma Applied testing Customized arrays Q4 2022 Investor Resource Book 47
Slide 48: PCR: One of the most widely used tools
PCR: One of the most widely used PCR / Nucleic acid amplification tools in molecular biology What is polymerase chain reaction (PCR)? The process of replicating a specific DNA fragment though a series of thermal cycling to generate thousands to millions of copies. Unlimited customization of arrays t
Slide 49: Digital PCR: New level of precision and sensitivity
Digital PCR: PCR / Nucleic acid amplification A new level of precision and sensitivity What is digital PCR? Digital PCR is a highly accurate approach for nucleic acid detection and quantification. The basic principle is the same as other PCR technologies Replicating a specific DNA fragment though a
Slide 50: Digital PCR: The latest generation of PCR technology
Digital PCR: The latest generation of PCR technology PCR / Nucleic acid amplification 1st generation 2nd generation 3rd generation Conventional PCR Quantitative RT-PCR (qPCR) Digital PCR (dPCR) Qualitative Relative quantification Absolute quantification Technically simple High accuracy, sensitivity
Slide 51: Leveraging novel technology with QIAcuity digital PCR
Leveraging novel technology with QIAcuity digital PCR PCR / Nucleic acid amplification Enabling access to the Easy-to-use comprehensive PCR market system vs. competition QIAcuity Differentiated nanoplate system QIAcuity One QIAcuity Four QIAcuity Eight Q4 2022 Investor Resource Book 51
Slide 52: QIAcuity digital PCR continuing to expand applications
Five pillars: QIAcuity digital PCR continuing to expand applications > 1,000 cumulative placements by end of H1 2022 Highlighted applications Cancer Biopharma Microbial Wastewater Proteomics research 10 new kits and and custom detection testing assays for Cell and Gene New automated workflow Therapy
Slide 53: PCR enzymes, reagents, and arrays for research workflows
PCR enzymes, reagents, and arrays PCR / Nucleic acid amplification for research workflows QuantiNova: Automatable, ultrafast kits QuantiNova: Automatable, ultrafast kits with in-process controlled safety measures with in-process controlled safety measures • PCR or 1-step & 2-step RT-PCR • Expert-des
Slide 54: Customized arrays: GeneGlobe design and analysis portal
Customized arrays: GeneGlobe design PCR / Nucleic acid amplification and analysis portal for biological content A world of genes, pathways and biological targets Find NGS, PCR and functional analysis assays in the relevant scientific context. Design custom products with full flexibility on target re
Slide 55: Genomics / NGS
Genomics / NGS Customers Universal NGS consumables Illumina collaboration NGS assays Life Sciences Academic Pharma Applied testing Molecular Diagnostics Bioinformatics solutions Q4 2022 Investor Resource Book 55
Slide 56: Universal NGS: QIAseq solutions
Universal NGS: QIAseq solutions providing Genomics / NGS high-performance chemistry Target enrichment and streamlined library preparation leveraging leading sample preparation and bioinformatics QIAGEN NGS differentiation NGS research market Superior technology performance for target enrichment >$80
Slide 57: Partnership to accelerate use of NGS in clinical decision-making
Partnership to accelerate use of NGS Genomics / NGS in clinical decision-making QIAGEN to develop and market NGS IVD kits (including CDx assays) for use on Illumina systems • Integrated with QIAGEN sample technologies, NGS IVD kits and bioinformatics solutions for “Sample to Insight” experience NGS
Slide 58: QIAGEN Digital Insights
QIAGEN Digital Insights: Turning Genomics / NGS sequencing data into clinically actionable information Bioinformatics [baɪ.oʊˌɪnfərˈmætɪks] is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformati
Slide 59: Partner of choice for actionable insights
The partner of choice for actionable insights Genomics / NGS from molecular and real-world data Multi-year partnership examples Preferred vendor for Deliver custom NGS Molecular oncology and Genomics England to patient data oncogenetic screening analyze 5 million interpretation for data in Japan’s l
Slide 60: Discovery Insights: Serving the research community
Discovery Insights: Serving the research community Genomics / NGS Example: Analyzing gene expression data from Sample to Insight Biological Freedom sample of Choice Sample Data to Information to Knowledge to data information knowledge to insight NGS library prep Normalization and QC Data Integration
Slide 61: Clinical Insights: Serving the diagnostic laboratories
Clinical Insights: Serving the diagnostic laboratories Genomics / NGS Software platform for scalable, standardized and reproducible variant interpretation VCF FASTQ Variant Variant alignment Variant assessment, Sequencing Final report and quality triage classification and control interpretation ONCO
Slide 62: Customer testimonial: Dr. Matthew Dodson
“The insights we gained through QIAGEN’s analysis point the way to a possible therapeutic target for disease intervention.” DR. MATTHEW DODSON Post-Doctoral Research Associate, Department of Pharmacology and Toxicology, University of Arizona Because of QIAGEN our customers are making improvements in
Slide 63: Sustainability at QIAGEN
Sustainability at QIAGEN Sample to Insight
Slide 64: Our vision is aligned with building a sustainable business
Our vision is aligned with building a sustainable business Vision MAKING IMPROVEMENTS IN LIFE Identity POSSIBLE Mission Q4 2022 Investor Resource Book 64
Slide 65: Our key levers: Sharpening our focus
Our key levers: Sharpening our focus to optimize our impact Aligned with U.N. Sustainable Development Goals Environment Social Responsibility for the Serving society environment • Access to healthcare • Minimize carbon footprint • Quality and product safety • Reduce, recycle and • Customer satisfact
Slide 66: Environment
Environment Q4 2022 Investor Resource Book 66
Slide 67: Environment: Reducing CO2e emissions
Environment: Reducing CO2e emissions across all operations Scope 1 and 2 Emissions Scope 3 Emissions 42% reduction by 2030 12.3% reduction by 2030 274k Scope 1 Combustion of fossil fuels Product Purchased Shipping disposal goods 11k Company Vehicles 10k QIAGEN 2021 Emissions Business Waste Scope 2 5
Slide 68: Environment: Integrating sustainability throughout the value chain
Environment: Integrating sustainability throughout the value chain Examples of sustainability in product design • Avoiding materials that cause a lot of damage when they are mined, cannot be recycled or do not decompose • Improving repairability, longevity, and allowing for reuse • Designing product
Slide 69: Environment: New eco-friendly versions of best-selling kits
Environment: New eco-friendly versions of best-selling kits QIAwave RNA Mini Kit / QIAwave DNA Blood & Tissue Kit / QIAwave Plasmid Miniprep Kit Waste tubes made from 100% Up to 63% post-consumer recycled plastic less plastic 86% reduction in concentrated buffers plastic materials Up to 42% less car
Slide 70: Social
Social Q4 2022 Investor Resource Book 70
Slide 71: Social: Equitable access to all QIAGEN products
Social: Aiming to provide equitable access to all QIAGEN products Working to ensure developing countries gain access to affordable diagnostics to help prevent and treat diseases Areas of accelerated efforts Committed to expanding screening for tuberculosis (TB) in regions with high rates of disease
Slide 72: Deepening commitment to diversity and inclusion
Deepening commitment to diversity and inclusion Diverse teams strengthen our organization through the variety of ideas, perspectives and approaches Executive Council on Diversity and Strategic initiative to Equal Opportunity Inclusion increase gender (ECEO) Ambassador Program diversity Created to dr
Slide 73: Governance
Governance Q4 2022 Investor Resource Book 73
Slide 74: Governance: Two-tier corporate structure
Governance: QIAGEN operates under a two-tier corporate structure Q4 2022 Investor Resource Book 74
Slide 75: Governance: International leadership team
Governance: International leadership team with over 200 years of combined industry experience Executive Committee Supervisory Board Chair Chief Executive Officer Thierry Bernard Lawrence A. Rosen Eva Pisa Joined 2015 Joined 2013 Joined 2022 Chief Financial officer Life Science Roland Sackers Thomas
Slide 76: Governance: Scientific Advisory Board
Governance: Scientific Advisory Board Chair Members Dr. Peter Kaspar Dr. Neville Sanjana Prof. Dr. Ross Levine Leadership positions at Core Faculty Member at the Roche Diagnostics and New York Genome Center bioMérieux during career in and Assistant Professor at diagnostics, Life Sciences New York Un
Slide 77: Find more information on QIAGEN.com
Find more information on QIAGEN.com Download QIAGEN’s Sustainability Report https://www.qiagen.com/sustainability Q4 2022 Investor Resource Book 77
Slide 78: Q3 2022 results
Q3 2022 results Exceeded outlook with 18% CER sales growth in non-COVID portfolio
Slide 79: Q3 2022: Double-digit CER growth in non-COVID portfolio
Q3 2022: Double-digit CER growth in non-COVID portfolio Net sales (CER)(1) Q3 2022: $533 million vs. ≥ $510 million outlook + 18% non-COVID products - 43% COVID-19 products Adjusted EPS (CER)(2) Q3 2022: $0.55 CER vs. ≥ $0.48 CER outlook 1) Net sales: $500 million, -7% at actual rates, 0% at CER vs.
Slide 80: Q3 2022: Solid performance with clear strategy execution
Q3 2022: Solid performance with clear strategy execution Ongoing strong trends Executing on key Strong operating Increasing 2022 in non-COVID business 2022 objectives cash flow full-year outlook +18% CER growth in 13 new biopharma assays +34% rise to $591 million in Sales: ~ $2.25 billion CER non-CO
Slide 81: Q3 2022: +18% CER growth in non-COVID product groups
Q3 2022: +18% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -7% -7% (0% CER) (0% CER) $535 $535 $500 $500 Sample - 2% CER Non-COVID 202 technologies product groups 183 376 + 18% CER 417 Diagnostic + 4%
Slide 82: Q3 2022: Solid demand for non-COVID products
Q3 2022: Solid demand for non-COVID products Americas • US: +7% CER non-COVID growth absorbed lower COVID sales • Brazil: Double-digit CER gains • Canada: Single-digit CER growth Europe / Middle East / Africa Americas EMEA Asia-Pacific / • Germany, Austria and Netherlands: Japan Strong double-digit
Slide 83: Q3 2022: Strong cash flow and healthy balance sheet
Q3 2022: Maintaining strong cash flow and healthy balance sheet Operating cash flow Free cash flow Leverage (In $ millions) (In $ millions) (Net debt / adj. EBITDA) Targeted investments into Five Pillars + 40% + 34% High level of R&D investments into menu expansion for QIAstat-Dx, NeuMoDx and 591 $5
Slide 84: QIAstat-Dx: Viral vesicular panel for monkeypox detection
QIAstat-Dx: Viral vesicular panel to address monkeypox detection RUO panel for research and epidemiological surveillance Pathogens differentiated by the QIAstat-Dx Viral Vesicular Panel Monkeypox virus (MPXV) clade 1 MPXV clade 2 Herpes simplex virus 1 Human herpes virus 6 Herpes simplex virus 2 Ent
Slide 85: NeuMoDx: Expanding CE-IVD menu to 16 tests
NeuMoDx: Expanding CE-IVD menu to 16 tests CE-IVD Hepatitis B Blood-borne viruses Hepatitis C Human Immunodeficiency Virus Cytomegalovirus Epstein Barr Virus 2.0 BK Virus Transplant Herpes Simplex Virus 1/2 Adenovirus Human Herpes Virus 6 Chlamydia / Gonorrhea Guillain–Barré syndrome Woman’s health
Slide 86: QIAcuity: Capturing biopharma growth opportunities
QIAcuity: Capturing attractive biopharma growth opportunities 13 new kits and and custom assays to serve Biopharma customers Biopharma customer preference: QIAcuity Eight • 10 QIAcuity Cell and Gene Therapy (CGT) dPCR Assays • 3 QIAcuity Residual DNA Quantification Kits • Custom assay design provide
Slide 87: Leveraging a comprehensive Liquid Biopsy portfolio
Leveraging a comprehensive Liquid Biopsy portfolio Addressing opportunities in research and clinical applications to unlock insights from blood Liquid Non-Invasive Cancer Growing Transplant Biopsy Prenatal research and monitoring market trends applications Testing (NIPT) oncology • Expansion of cfDN
Slide 88: Committed to building a sustainable business
Committed to building a sustainable business QIAGEN 2021 Sustainability Report Published in August 2022 https://www.qiagen.com/sustainability Environment Social Governance Visible progress in lowering Committed to leaving Ensuring responsible business greenhouse gas intensity no one behind conduct f
Slide 89: Key messages
Key messages 01 Q3 2022: Solid results exceeded outlook, driven by 18% CER sales growth in non-COVID portfolio 02 FY 2022 outlook: Increased sales and adj. EPS due to Q3 performance, reaffirming double-digit CER non-COVID sales growth 03 Making progress on advancing strategy focused on 5 Pillars of
Slide 90: Appendix
Appendix
Slide 91: Q4 and FY 2022: Outlook and assumptions
Q4 and FY 2022: Outlook and assumptions (As of November 7, 2022) Q4 2022 outlook Updated FY 2022 outlook ~ $2.25 billion CER Net sales > $520 million CER (Previously: ≥ $2.2 bn CER) Anticipated currency impact(1) Adverse impact of ~ -7 p.p. Adverse impact of ~ -6 p.p. ~ $2.40 CER Adjusted EPS(2) > $
Slide 92: Q3 2022: Consolidated Statements of Income
Q3 2022: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) September 30, 2022 September 30, 2021 Net sales 499,631 534,745 Cost of sales: Cost of sales 163,511 181,214 Acquisition-related intangible amortization 15,069 16,314 Tota
Slide 93: 9M 2022: Consolidated Statements of Income
9M 2022: Consolidated Statements of Income (unaudited) Nine months ended Nine months ended (In $ thousands, except share data) September 30, 2022 September 30, 2021 Net sales 1,643,534 1,669,259 Cost of sales: Cost of sales 531,010 540,576 Acquisition-related intangible amortization 45,485 51,687 To
Slide 94: 2022: Quarterly sales by product group
2022: Quarterly sales by product group (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 9M 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 265 17% 22% 178 -12% -7% 183 -10% -2% 626 -1% 5% Diagnostic solu
Slide 95: 2021: Quarterly sales by product group
2021: Quarterly sales by product group (In $ millions at actual rates / Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 227 47% 42% 203 1% -3% 202 -5% -6% 218 -7% -5% 851 6% 4% Diagnos
Slide 96: 2022: Sales by non-COVID and COVID-19 product groups
2022: Sales by non-COVID and COVID-19 product groups (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 9M 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 400 10% 14% 423 4% 10% 417 11% 18% 1,240 8% 1
Slide 97: 2021: Sales by non-COVID and COVID-19 product groups
2021: Sales by non-COVID and COVID-19 product groups Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 364 20% 16% 408 57% 52% 376 18% 17% 400 8% 10
Slide 98: 2022: Quarterly sales by product type, customer class and region
2022: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2022 Q2 2022 Q3 2022 Q4 2022 9M 2022 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 561 13% 17% 453 -9% -
Slide 99: 2021: Quarterly sales by product type, customer class and region
2021: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 498 53% 48% 498 33% 2
Slide 100: Q3 and 9M 2022: Reconciliation adjusted results
Q3 and 9M 2022: Reconciliation adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted sales profit income income tax rate income EPS Third quarter 2022 Reported results 499.6 321.1 97.7 95.7 (13.3) 14% 82.4 0.36 Adjustments Business integration, ac
Slide 101: Footnotes for reconciliation adjusted results
Q3 and 9M 2022: Footnotes for reconciliation adjusted results (unaudited) a) Results for 2022 include costs for acquisition projects, including continued integration activities at NeuMoDx, as well as costs and impairments related to our business in Russia, Ukraine and Belarus. Additionally, these co
Slide 102: 2022: Quarterly income statement summary
2022: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2022 Q2 2022 Q3 2022 Q4 2022 9M 2022 Net sales 628.4 515.5 499.6 1,643.5 Net sales (CER) 654.1 543.8 533.5 1,731.3 Gross profit 415.0 331.0 321.1 1,067.0 Gross profit margin 66.0% 64.2% 64.3% 6
Slide 103: 2021: Quarterly and full-year income statement summary
2021: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 Net sales 567.2 567.3 534.7 582.4 2,251.7 Gross profit 370.6 369.2 337.2 373.8 1,450.8 Gross profit margin 65.3% 65.1% 63.1% 64.2% 64.4% Adjus
Slide 104: Consolidated Balance Sheets
Consolidated Balance Sheets September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2022 2021 (In $ thousands, except par value) 2022 2021 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 1,271,597 880,516 Current portion of long-term d
Slide 105: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Nine months ended September 30, September 30, Nine months ended September 30, September 30, (In $ thousands) 2022 2021 (In $ thousands) 2022 2021 Cash flows from operating activities: Cash flows from financing activities: Net income 334,367 383,413 P
Slide 106: Q3 and 9M 2022: Currency impact
Q3 and 9M 2022: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2022 0 U.S. dollar 274.2 274.2 51% 0.0 Euro 102.5 119.9 22% 17.4 British pound 10.5 12.1 2% 1.6 Japanese yen 12.9 16.2 3% 3.3 Other currencies 99.5 111.0
Slide 107: Employees as of September 30, 2022
Employees as of September 30, 2022 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q3 2022 Q2 2022 Change Production 424 1,277 150 1,851 1,845 0% R&D 214 767 59 1,040 1,036 0% Sales 605 894 816 2,315 2,294 1% Marketing 73 210 75 358 344 4% Administration 78 417 165 660
Slide 108: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q4 / FY 2022 results February 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q1 2023 results May 2023 E-mail: phoebe.loh@qiagen.com Annual General Meeting June 2023 Alexandra Koenig Share information Coordinator Inv